The 2004 International AIDS Conference and how to globally counter HIV/AIDS

HIV Clinical Trials

Volumn 6, Issue 1, 2005, Pages 43-49

  Idemyor, Vincent ^a,b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b NONE   (United States)

Author keywords

Access for all; Comprehensive programs; HIV AIDS

Indexed keywords

ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; ENFUVIRTIDE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADVERTIZING; AFRICA; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD BANK; CLINICAL TRIAL; CONDOM; CONTINUING EDUCATION; COOPERATION; DEATH; DRUG POTENTIATION; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE ORGANIZATION; HEALTH EDUCATION; HEALTH PRACTITIONER; HEALTH PROGRAM; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN RIGHTS; INCIDENCE; INFORMATION DISSEMINATION; INTRAVENOUS DRUG ABUSE; LEADERSHIP; MALARIA; MASS MEDIUM; MEDICAL DOCUMENTATION; MONITORING; MYCOBACTERIUM TUBERCULOSIS; PATHOGENESIS; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; PLACENTAL TRANSFER; PLASMODIUM MALARIAE; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC HEALTH SERVICE; RURAL AREA; SCREENING TEST; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SOCIAL WORK; THAILAND; TREATMENT PLANNING; TUBERCULOSIS; URBAN AREA;

EID: 17344365355     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/RM35-RE2A-J9L2-8J47     Document Type: Article

References (8)

1. Gathe JC, Washington MY, Mayberry C, Piot D, Nemecek J. IMANI-1 TC3WP. Single drug HAART-proof of concept study. Pilot study of the safety and efficacy of Kaletra (LPV/r) as single drug HAART in HIV+ ARV-naïve patients-interim analysis of subjects completing final 48 week data. In: Program and abstracts of the XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract MoOrB1057.
2. Ruane P, Luber A, Gaultier C, et al. Maintenance therapy using lopinavir/ritonavir (LPV/r) alone with well-controlled HIV Infection. In: Program and abstracts of the XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract TuPeB4577.
3. von Hentig NH, Mueller A, Haberl A, et al. The ATSAQ-1 cohort study: pharmacokinetic interactions of atazanavir (AZV) and saquinavir (SQV) in a ritonavir (RTV) boosted protease inhibitor therapy regimen. In: Program and abstracts of the XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract WeOrB1235.
4. Arasteh K, Lazzariri A, Clotet B, et al. TORO: 96 week virological and immunological response and safety evaluation of enfuvirtide with an optimized background regimen. In: Program and abstracts of the XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract MoOrB1058.
5. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004;351(3):217-218.
6. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;351(3):229-240.
7. Ferris DC, Dawood H, Chiasson MA, et al. Self-reported adherence to antiretroviral therapy and virologic outcomes in HIV-infected persons in Durban, KwaZulu Natal, South Africa. In: Programs and abstracts of the XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract WePeB5829.
8. Oyugi JH, Byakika JT, Raglang K, et al. Treatment outcomes and adherence to generic triomune and maxivir therapy in Kampala, Uganda. In: Program and abstracts of the XV International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract WeOrB1323.